FROM S&R FARMACEUTICI HELP IN DIAGNOSING PROSTATE CANCER

iXip is the name of the early measurement method owned by the company based in Bastia Umbria – It was presented to the association of urologists operating in private hospitals

An early method for the measurement of prostate health which informs in the event of probable cancer, thus avoiding the need for more invasive practices like biopsies, should certain values be detected. iXip is a diagnostic index that helps distinguish prostate cancer from benign pathologies like hypertrophy or inflammation, with a simple lab test, a blood test.

This modern diagnostic device owned by S&R Farmaceutici from Bastia Umbra, was presented to the executive Committee of Urop, an association of urologists operating in private hospitals, on occasion of a meeting at S&R Farmaceutici. Today other lab tests can distinguish prostate cancer from other benign pathologies, including Phi, Pca3, the 4 K score, as well as Psa values (prostate specific antigene) in the blood, or multiparameter magnetic resonance.

Giammario Piras, head of business development at S&R and project leader of iXip, explained how – “iXip has not been designed to replace Psa or other diagnostic tests, but rather to complete diagnostic accuracy; iXip intercepts a need of Italian urology, because prostate cancer is the most prevalent in adult males. The doctor can immediately estimate potential aggressiveness of the tumour and promptly plan treatment strategies for their patient”.

Currently a urologist faced with a patient with prostate disease symptoms or who wishes to receive prostate prostate cancer screening must often prescribe ‘unpleasant’ tests, like a digital-rectal examination or transrectal prostate ultrasound.

The President of Urop Angelo Porreca declared how “We were impressed by the dynamism and practicality of S&R Farmaceutici, without a doubt the opportunity to work together will arise. Together we analysed the paths, validity and criticalities of this test for the early diagnosis of prostate carcinoma and to understand how iXip can help us avoid lots of biopsies and useless invasive procedures for our patients”.

Stefano Pecoraro, president of the national Urop Congress also spoke in addition to the top management of S&R farmaceutici (the chairman Romolo Rossi, vice chairman Silvia Rossi, chief executive officer Mauro Dionigi, general manager Lucio Leonardi). The thirteenth congress will take place in Salerno, from 24th to 26th May, with the participation of the company based in Bastia Umbra.

Pecoraro affirmed how “The national Congress is a crucial moment for us regarding all that has been done in a year of associative activity. It will focus on what has been done in the clinical, surgical field and beyond and will in part be dedicated to surgical activities and in part to convention activities, with workshops focused on various diseases. S&R will be present in the session dedicated to benign prostate hypertrophy and feminine vaginal cystitis”.